Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)
Servier
Servier
Sumitomo Pharma America, Inc.
Wake Forest University Health Sciences
Radiation Therapy Oncology Group
Isarna Therapeutics GmbH
INSYS Therapeutics Inc